Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)

Trial Profile

Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Asthenia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PREPARE
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Feb 2018 Planned End Date changed from 28 Feb 2023 to 28 Feb 2022.
    • 21 Feb 2018 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top